282 related articles for article (PubMed ID: 12162735)
1. Annular alpha-synuclein protofibrils are produced when spherical protofibrils are incubated in solution or bound to brain-derived membranes.
Ding TT; Lee SJ; Rochet JC; Lansbury PT
Biochemistry; 2002 Aug; 41(32):10209-17. PubMed ID: 12162735
[TBL] [Abstract][Full Text] [Related]
2. Vesicle permeabilization by protofibrillar alpha-synuclein: implications for the pathogenesis and treatment of Parkinson's disease.
Volles MJ; Lee SJ; Rochet JC; Shtilerman MD; Ding TT; Kessler JC; Lansbury PT
Biochemistry; 2001 Jul; 40(26):7812-9. PubMed ID: 11425308
[TBL] [Abstract][Full Text] [Related]
3. Alpha-synuclein, especially the Parkinson's disease-associated mutants, forms pore-like annular and tubular protofibrils.
Lashuel HA; Petre BM; Wall J; Simon M; Nowak RJ; Walz T; Lansbury PT
J Mol Biol; 2002 Oct; 322(5):1089-102. PubMed ID: 12367530
[TBL] [Abstract][Full Text] [Related]
4. Fibrils formed in vitro from alpha-synuclein and two mutant forms linked to Parkinson's disease are typical amyloid.
Conway KA; Harper JD; Lansbury PT
Biochemistry; 2000 Mar; 39(10):2552-63. PubMed ID: 10704204
[TBL] [Abstract][Full Text] [Related]
5. Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy.
Conway KA; Lee SJ; Rochet JC; Ding TT; Williamson RE; Lansbury PT
Proc Natl Acad Sci U S A; 2000 Jan; 97(2):571-6. PubMed ID: 10639120
[TBL] [Abstract][Full Text] [Related]
6. Beta-synuclein inhibits formation of alpha-synuclein protofibrils: a possible therapeutic strategy against Parkinson's disease.
Park JY; Lansbury PT
Biochemistry; 2003 Apr; 42(13):3696-700. PubMed ID: 12667059
[TBL] [Abstract][Full Text] [Related]
7. Interactions among alpha-synuclein, dopamine, and biomembranes: some clues for understanding neurodegeneration in Parkinson's disease.
Rochet JC; Outeiro TF; Conway KA; Ding TT; Volles MJ; Lashuel HA; Bieganski RM; Lindquist SL; Lansbury PT
J Mol Neurosci; 2004; 23(1-2):23-34. PubMed ID: 15126689
[TBL] [Abstract][Full Text] [Related]
8. Molecular crowding accelerates fibrillization of alpha-synuclein: could an increase in the cytoplasmic protein concentration induce Parkinson's disease?
Shtilerman MD; Ding TT; Lansbury PT
Biochemistry; 2002 Mar; 41(12):3855-60. PubMed ID: 11900526
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of fibrillization and accumulation of prefibrillar oligomers in mixtures of human and mouse alpha-synuclein.
Rochet JC; Conway KA; Lansbury PT
Biochemistry; 2000 Sep; 39(35):10619-26. PubMed ID: 10978144
[TBL] [Abstract][Full Text] [Related]
10. The association of alpha-synuclein with membranes affects bilayer structure, stability, and fibril formation.
Zhu M; Li J; Fink AL
J Biol Chem; 2003 Oct; 278(41):40186-97. PubMed ID: 12885775
[TBL] [Abstract][Full Text] [Related]
11. ABri peptide associated with familial British dementia forms annular and ring-like protofibrillar structures.
Srinivasan R; Marchant RE; Zagorski MG
Amyloid; 2004 Mar; 11(1):10-3. PubMed ID: 15185493
[TBL] [Abstract][Full Text] [Related]
12. Characterization of cytoplasmic alpha-synuclein aggregates. Fibril formation is tightly linked to the inclusion-forming process in cells.
Lee HJ; Lee SJ
J Biol Chem; 2002 Dec; 277(50):48976-83. PubMed ID: 12351642
[TBL] [Abstract][Full Text] [Related]
13. Dependence of alpha-synuclein aggregate morphology on solution conditions.
Hoyer W; Antony T; Cherny D; Heim G; Jovin TM; Subramaniam V
J Mol Biol; 2002 Sep; 322(2):383-93. PubMed ID: 12217698
[TBL] [Abstract][Full Text] [Related]
14. Accelerated in vitro fibril formation by a mutant alpha-synuclein linked to early-onset Parkinson disease.
Conway KA; Harper JD; Lansbury PT
Nat Med; 1998 Nov; 4(11):1318-20. PubMed ID: 9809558
[TBL] [Abstract][Full Text] [Related]
15. Vesicle permeabilization by protofibrillar alpha-synuclein is sensitive to Parkinson's disease-linked mutations and occurs by a pore-like mechanism.
Volles MJ; Lansbury PT
Biochemistry; 2002 Apr; 41(14):4595-602. PubMed ID: 11926821
[TBL] [Abstract][Full Text] [Related]
16. Inhibiting aggregation of alpha-synuclein with human single chain antibody fragments.
Emadi S; Liu R; Yuan B; Schulz P; McAllister C; Lyubchenko Y; Messer A; Sierks MR
Biochemistry; 2004 Mar; 43(10):2871-8. PubMed ID: 15005622
[TBL] [Abstract][Full Text] [Related]
17. Biophysical properties of the synucleins and their propensities to fibrillate: inhibition of alpha-synuclein assembly by beta- and gamma-synucleins.
Uversky VN; Li J; Souillac P; Millett IS; Doniach S; Jakes R; Goedert M; Fink AL
J Biol Chem; 2002 Apr; 277(14):11970-8. PubMed ID: 11812782
[TBL] [Abstract][Full Text] [Related]
18. Neurodegenerative disease: amyloid pores from pathogenic mutations.
Lashuel HA; Hartley D; Petre BM; Walz T; Lansbury PT
Nature; 2002 Jul; 418(6895):291. PubMed ID: 12124613
[TBL] [Abstract][Full Text] [Related]
19. Zeroing in on the pathogenic form of alpha-synuclein and its mechanism of neurotoxicity in Parkinson's disease.
Volles MJ; Lansbury PT
Biochemistry; 2003 Jul; 42(26):7871-8. PubMed ID: 12834338
[TBL] [Abstract][Full Text] [Related]
20. Metal-catalyzed oxidation of alpha-synuclein: helping to define the relationship between oligomers, protofibrils, and filaments.
Cole NB; Murphy DD; Lebowitz J; Di Noto L; Levine RL; Nussbaum RL
J Biol Chem; 2005 Mar; 280(10):9678-90. PubMed ID: 15615715
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
